Key Takeaways
- Earnings recovery on track, led by margin: EBITDA rose 14% YoY and contribution margin expanded ~390 bps, driven by lower input costs and better product mix, even as revenue grew only ~2%.
- Balance sheet repair is the real story: Net debt fell $806 mn YoY and net debt-to-EBITDA improved from 5.4x to 2.6x, supported by a Rs. 3,300 crore working capital reduction and strong cash generation.
- Brazil remains the swing factor: UPL Corp revenue declined 3% as insecticide pricing pressure and deliberate shipment phasing into Q2 weighed on LATAM, but a stronger order book and normalised channel inventory underpin a second-half-weighted growth plan.
- Advanta delivered volume but not margin: 12% volume growth drove double-digit revenue, yet EBITDA rose only 5% as higher raw seed costs, lower yield recovery, and capacity-building overhead compressed margins.
- What to watch next quarter: Whether the promised LATAM recovery materialises, the pace of Advanta margin repair, and any concrete update on the newly announced platform restructuring exploration.
Margin & Earnings Quality
- Contribution margin leap: Improved ~390 bps to over 43%, driven by favourable product mix, higher capacity utilisation, and lower input costs, mainly in the Crop Protection segment.
- COGS reduction is structural: UPL Corp entered the year with fresh inventory at lower replacement cost after reducing stock to a ~90-day forward cover; roughly $30 mn of the $58 mn COGS improvement came from this lower cost base, and the benefit is expected to carry through the rest of the year.
- Operating leverage returning: The remaining ~$20 mn of COGS improvement came from higher plant utilisation as production ramped back to normal levels after being cut in the first half of last year; this benefit also continues.
- SG&A spike is non-cash and temporary: SG&A rose 11% YoY, driven by a $13 mn ECL accrual on a Brazil distributor's phased payment plan under an extrajudicial process; management expects this non-cash impact to unwind over the recovery horizon and sees no further ECL issues given the lack of significant customer concentration.
- Finance costs trending down: Net finance cost in dollar terms fell 17% YoY due to debt prepayment and tighter working capital; the published financials include exchange losses, so the underlying interest cost trajectory is healthier than the headline suggests.
Bikash Prasad: "Only from accounting standard perspective, we had to recognize this. But overall, our net credit exposure has been reduced. We have taken this impact, an accounting non-cash impact but we feel that over the period of recovery, this entire amount will get reversed."
Balance Sheet & Deleveraging
- Net debt reduction: Net debt fell Rs. 6,129 crores ($806 mn) YoY, though it rose sequentially from March 2025 due to the $400 mn perpetual bond redemption and seasonally higher working capital.
- Leverage ratios transformed: Net debt-to-EBITDA improved from 5.4x to 2.6x, and net debt-to-equity from 0.9x to 0.6x, driven by operational performance and capital efficiency.
- Working capital discipline: Net working capital dropped Rs. 3,300 crores YoY to Rs. 11,025 crores, with days reduced from 121 to 86, supported by tighter inventory management and improved collections.
- Factoring as a deliberate risk tool: Management views non-recourse factoring as a strong risk mitigation tool given market volatility; the factoring book declined $45 mn in Q1 versus Q4 in line with normal seasonality and is expected to stay in a similar range to last year, around $1 bn.
- Supplier confidence improving: Suppliers are offering better terms, including longer payment periods and more favourable pricing, reflecting confidence in UPL's strengthened balance sheet.
- Rights issue proceeds incoming: The second and final call of Rs. 180 per partly paid share will bring in Rs. 1,688 crores ($200 mn) by end of September, subject to regulatory clearance.
- Strategic options under review: UPL is engaging advisors to explore restructuring and unlocking value across all platforms; management stated it is too early to comment on structure or timeline but will share material developments when they arise.
Bikash Prasad: "we are extremely focused on further deleveraging and are actively evaluating various strategic options. At this point in time, we do not have anything material to share with you, but as and when there is something significant, we will definitely share it with you."
Regional & Platform Performance
| Platform / Region | Trend | Commentary |
|---|---|---|
| UPL SAS (India) | ▲ Strong | Revenue up 13% (9% volume, 4% price); contribution margin up ~450 bps to 32.7%; EBITDA margin up 540 bps to 22.3%, helped by new launches. |
| Advanta | ▲ Volume, ▼ Margin | Revenue up double digits on 12% volume growth; EBITDA up only 5% as higher raw seed costs, lower yield recovery from rainfall, and capacity-building overhead compressed margins. |
| SUPERFORM | ▲ Growth | Revenue up 9% led by volume; SSC segment grew 21%; contribution margin up 50 bps to 24.9%. |
| UPL Corp | ▼ Slight decline | Revenue down ~3% on insecticide pricing pressure in Brazil and deliberate Q1-to-Q2 shipment phasing; fungicides and herbicides posted robust growth. |
| Latin America | ▼ Decline | Revenue down ~12%; Brazil impacted by pricing pressure on select molecules and product phasing shift. |
| North America | ▲ Growth | Up 6% driven by robust herbicide portfolio (metribuzin, clethodim, s-metolachlor) and higher mancozeb and acephate revenue. |
| Europe | ▲ Growth | Up 5% on higher herbicide and fungicide volumes; strong performance in Germany, Italy, Belgium, Spain. |
| Africa & Asia-Pacific | ▬ Flat to slightly down | Growth in Indonesia, Japan, and Africa offset by pricing headwinds in China and a few other markets; net 2% lower. |
- Global crop protection demand healthy: Strong agchem demand at the farm gate level persists despite low row crop commodity prices; farmer margin pressure is shifting demand toward the post-patent side, where UPL is well positioned. Channel inventory for UPL stock has returned to normal levels, and the order book is stronger than this time last year.
Mike Frank: "We continue to see strong agchem demand at the farm gate level, despite low commodity prices for row crops. Farmer margins are under pressure in most markets, and this is creating more demand on the post-patent side of our business."
Pricing, Phasing & the Brazil Recovery Bet
- Pricing declined modestly: Overall pricing fell ~1%, driven mainly by the insecticide portfolio in Brazil where certain categories became more competitive and retailers negotiated harder; management adjusted pricing selectively in that segment.
- Volume-led growth ahead: For Q2 through Q4, growth is expected to come almost exclusively from volume; on a blended average basis, pricing is expected to be relatively flat versus last year.
- Green shoots from China: Management noted price increases emerging from China on key molecules including clethodim, mancozeb, and S-metolachlor, creating an opportunity to review pricing globally; any sustained improvement would be upside to the base plan, which assumes consistent China pricing.
- Deliberate Q2 phasing: UPL is purposely shifting some Brazil business into Q2 to manage working capital, despite a strong order book; insecticides for the upcoming soybean season are still being negotiated, whereas last year there was less delay.
- Tariff impact contained: The duty differential between China and India moved from 25% to 30% after the new US tariff announcement, leaving UPL better off compared to last year; North America portfolio exposure to tariffs is less than 10%, and the tariff announcement does not change financial outcome expectations for this year.
Mike Frank: "I would say there are a couple of key molecules in our portfolio where we've seen some increase in price. One example is clethodim, and another is mancozeb, where we're starting to see some prices increase out of China. This is giving us the opportunity to review our pricing globally, which we are actively doing."
Advanta: Growth with Margin Pressure
- Volume engine intact: 12% volume expansion drove double-digit revenue growth, led by corn in India and Thailand, and grain sorghum and sunflower in Argentina.
- Three margin headwinds: Raw seed procurement costs increased, particularly in the non-GM tropical yellow corn segment where corn prices stayed stable; recovery rates from raw corn to fresh packed corn declined due to rainfall during harvest; and overhead rose from new-year recruitment.
- Costs are partly transient: The raw seed cost and yield recovery impact is already captured in finished good inventory and will not repeat; overhead has two components: permanent employees for capacity building over the next 3–4 quarters, and seasonal employees that will come down in about a month.
- Q2 improvement expected: Management stated things are likely to improve significantly in Q2.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 4% to 8% YoY growth | FY26 |
| EBITDA growth | 10% to 14% YoY growth | FY26 |
| Growth weighting | Growth weighted towards second half of the year | FY26 |
| New product revenue | $130 mn from new product launches, mostly in H2 | FY26 |
| LATAM recovery | Optimistic for recovery in Q2, good growth in H2 | Q2 FY26 onwards |
| Pricing trajectory | Volume-led growth; blended pricing flat vs last year | Q2–Q4 FY26 |
| COGS margin benefit | Benefit from lower-cost inventory to carry through | Rest of FY26 |
| Rights issue proceeds | Rs. 1,688 crores ($200 mn) received | By end of September 2025 |
| Effective tax rate | 15% to 17% range for modelling | FY26 |
| Deleveraging | Gearing lower than last year even after perpetual bond repayment | Over next 1–2 years |
| Strategic options | Advisors engaged; no material development yet | Too early to comment |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹9,216 cr, ~2% higher YoY; driven by 1% increase in pricing and favorable exchange impact |
| Contribution margin | 43.4%, improvement of ~390 bps YoY |
| EBITDA | ₹1,303 cr, up 14% YoY |
| EBITDA margin | 14.1%, improved 150 bps YoY |
| Profit after tax (PAT) | Loss of ₹176 cr, improved from loss of ₹528 cr YoY |
| Profit after tax and minority interest (PATMI) | Loss of ₹88 cr, improvement of ~₹300 cr YoY |
| Net finance costs | ₹631 cr, down from ₹740 cr YoY |
| Net debt | ₹21,371 cr ($2,492 mn), reduction of ₹6,129 cr or $806 mn YoY |
| Net debt-to-EBITDA | 2.6x, improved from 5.4x YoY |
| Net working capital days | 86 days, reduction of 35 days YoY |
| UPL Corp revenue growth | -3% YoY, primarily due to product phasing and insecticide pricing pressure in LATAM |
| UPL Corp EBITDA growth | 23% YoY, margin expansion of more than 135 bps |
| UPL SAS (India CP) revenue growth | 13% YoY, led by 9% volume growth and 4% improved pricing |
| Advanta (Seeds) revenue growth | Double-digit YoY, fueled by 12% volume expansion |
| SUPERFORM revenue growth | 9% YoY, led by volume; SSC segment grew 21% YoY |
| FY26 guidance: revenue growth | 4% to 8% vs FY25 |
| FY26 guidance: EBITDA growth | 10% to 14% vs FY25 |